Editorial
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Obstet Gynecol. Feb 10, 2016; 5(1): 1-4
Published online Feb 10, 2016. doi: 10.5317/wjog.v5.i1.1
Clinical applicability of immunotherapy of cervical intraepithelial neoplasia
Margot Koeneman, Roy Kruitwagen, Arnold-Jan Kruse
Margot Koeneman, Roy Kruitwagen, Arnold-Jan Kruse, Department of Obstetrics and Gynecology, Maastricht University Medical Center, 6202 AZ Maastricht, the Netherlands
Margot Koeneman, Roy Kruitwagen, Arnold-Jan Kruse, GROW - School for Oncology and Developmental Biology, Maastricht University, 6202 AZ Maastricht, the Netherlands
Author contributions: Koeneman M, Kruitwagen R and Kruse AJ conceived the issues which formed the content of the manuscript and wrote the manuscript.
Conflict-of-interest statement: The authors have no conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Arnold-Jan Kruse, MD, PhD, Department of Obstetrics and Gynecology, Maastricht University Medical Center, Postbus 5800, 6202 AZ Maastricht, the Netherlands. arnoldjankruse@hotmail.com
Telephone: +31-43-3874242
Received: June 29, 2015
Peer-review started: July 1, 2015
First decision: September 30, 2015
Revised: October 10, 2015
Accepted: November 10, 2015
Article in press: November 11, 2015
Published online: February 10, 2016
Processing time: 216 Days and 16.2 Hours
Core Tip

Core tip: Immunotherapy for cervical intraepithelial neoplasia (CIN) is discussed in light of the natural history of CIN. The pros and cons of the current standard therapy (large loop excision of the transformation zone) and immunotherapy, potential side effects, and available evidence supporting the use of immunotherapy in CIN are addressed.